Metastatic Tumors

Slide 1 · Metastatic tumors involving bone

Dissemination · skeletal patterns · tumor–bone signaling · clinical consequences

Extraosseous cancer

Skeletal involvement

Bone-cell response

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Distinguish skeletal metastases from primary bone neoplasms.

Identify the major pathways and sources of secondary bone tumors.

Interpret osteolytic, osteoblastic, and mixed skeletal responses.

Explain interactions between metastatic tumor cells and bone.

Relate skeletal involvement to prognosis and treatment aims.

Slide 3 · Skeletal metastasis: Disease definition

Malignant neoplasm originating outside bone subsequently involves the skeleton.

Secondary skeletal disease can arise by local extension or distant dissemination.

It is distinguished conceptually from a tumor that arises within bone.

Its pathologic behavior reflects both tumor cells and the responding bone microenvironment.

Slide 4 · Metastases dominate skeletal malignancy

Secondary involvement

Extraosseous cancer reaches bone.

Most common malignant category in the skeleton.

Multiple lesions are typical, but not obligatory.

Primary bone malignancy

Malignant tumor originates in bone.

Far less frequent overall than metastases.

Requires separate classification by bone tumor lineage.

Frequency statements refer to skeletal malignancies, not all bone lesions.

Slide 5 · What the skeleton contributes to the disease

Vascular access

Routes for arriving cancer cells

Includes Batson venous plexus

Bone cells

Osteoclast resorption

Osteoblast formation

Matrix signals

TGF-β, IGF-1, FGF

Released with resorption

Tumor growth and the skeletal response are mechanistically linked.

Slide 6 · Bone remodeling is a coordinated sequence

Osteoclast attachment

Initiates matrix resorption

Bone resorption

Removes mineralized matrix

Osteoblast activity

New bone synthesis

Normal bone remodeling depends on coupling of resorption and formation.

Slide 7 · Basic multicellular unit: Two cooperating cell systems

Osteoclast system

Resorbs existing mineralized bone.

Differentiation and survival depend on regulatory signals.

Excess activity favors osteolysis.

Osteoblast system

Produces new bone matrix.

Wnt signaling supports osteoblast function.

Excess activity favors osteoblastic lesions.

Background physiology from the same Robbins chapter.

Slide 8 · RANK–RANKL promotes osteoclast differentiation

Osteoblast / stromal cell

Expresses RANK ligand

RANK on precursor

Receives RANKL signal

NF-κB signaling

Promotes osteoclast formation / survival

RANKL signaling provides physiologic context for osteoclast-mediated bone loss.

Slide 9 · Osteoprotegerin counterbalances RANKL

RANKL available

RANK on precursor can bind ligand.

Osteoclast formation is favored.

More resorption can occur.

OPG binds RANKL

Decoy receptor intercepts the ligand.

RANK stimulation decreases.

Osteoclast formation is restrained.

Opposition is a background mechanism; The metastatic-tumor paragraph does not specify which mediators alter OPG.

Slide 10 · Wnt signaling and bone formation

Wnt proteins

Signaling input

LRP5/LRP6–β-catenin

Osteoblast pathway

Bone formation

Osteoblastic response

In metastases, tumor-secreted Wnt proteins may stimulate osteoblasts.

Slide 11 · The two skeletal effector pathways

Osteoclast-led response

Increased bone resorption.

Creates or enlarges osteolytic defects.

Tumor-derived signals are upstream.

Osteoblast-led response

Increased new bone formation.

Produces osteoblastic skeletal lesions.

Wnt is one candidate tumor-derived driver.

These represent dominant responses rather than absolute biologic categories.

Slide 12 · Three routes to skeletal involvement

Direct extension

Primary tumor grows toward adjacent bone

Lymphatic / blood

Tumor disseminates through vascular pathways

Batson plexus

Intraspinal venous route to vertebrae

All three routes are explicitly named.

Slide 13 · Direct extension: Contiguous invasion

Extraosseous cancer

Located near bone

Local tissue extension

Grows through adjacent structures

Skeletal invasion

Bone becomes involved

This is an alternative to distant hematogenous spread.

Slide 14 · Hematogenous dissemination to bone

Primary cancer

Origin outside skeleton

Bloodborne tumor cells

Systemic dissemination

Secondary skeletal focus

Colonization of bone

The source identifies hematogenous dissemination without prescribing a universal sequence of molecular steps.

Slide 15 · Lymphatic dissemination is an additional route

Robbins explicitly lists lymphatic dissemination among skeletal metastatic pathways.

Lymphatic spread should not be treated as identical to direct contiguous extension.

Different tumors may reach bone through more than one pathway.

Interpretive caution

The source does not quantify the contribution of each route.

Slide 16 · Batson venous plexus: An intraspinal pathway

Cancer cells

Available to venous routes

Batson plexus

Intraspinal venous network

Vertebral involvement

Skeletal metastasis

The Batson plexus as a route of intraspinal seeding.

Slide 17 · Routes cannot be inferred from imaging pattern alone

What imaging may describe

Location of the involved bone.

Lytic, blastic, or mixed appearance.

Single versus multiple foci.

What requires caution

Exact route of tumor travel.

Definitive primary site based only on pattern.

Proportion attributable to any one pathway.

Interpretive limitation derived from the separation of route, distribution, and response in the source.

Slide 18 · Common adult sources of skeletal metastases

Prostate

Carcinoma

Often blastic

Breast

Carcinoma

Lytic lesions described

Kidney

Carcinoma

Lytic or solitary

Lung

Carcinoma

Major adult source

These four carcinomas account for more than 75% of adult skeletal metastases.

Slide 19 · Adult skeletal metastases: The >75% statement

In adults, prostate, breast, kidney, and lung carcinomas account for more than 75% of skeletal metastases.

The percentage applies to adult skeletal metastases, not all metastatic disease.

The group contains frequent primary sources; It is not an exclusive list.

Scope of evidence

“More than 75%” is explicitly stated.

Slide 20 · No primary cancer is categorically excluded

Any cancer can spread to bone.

The common adult sources are epidemiologically important, not biologically exclusive.

Primary site, skeletal pattern, and number of foci are separate dimensions of interpretation.

Teaching implication

Avoid equating an uncommon primary source with impossibility.

Slide 21 · Pediatric metastatic tumors: A distinct spectrum

Neuroblastoma

Commonly listed source of bone metastases

In children

Wilms tumor

Commonly listed source of bone metastases

In children

Sarcomas

Osteosarcoma · Ewing sarcoma

Rhabdomyosarcoma

The childhood list is categorical; Robbins does not supply a numerical rank order or proportional distribution.

Slide 22 · Adult and pediatric source categories differ

Adults

Prostate, breast, kidney, and lung carcinomas dominate.

Adult proportion is specifically quantified as >75%.

Patterns may suggest—but cannot prove—the source.

Children

Neuroblastoma and Wilms tumor are included.

Osteosarcoma, Ewing sarcoma, rhabdomyosarcoma also listed.

No comparable numeric proportion is given.

The two age groups must not share an invented percentage.

Slide 23 · Typical spatial distribution: Multifocal and axial

Multifocal

Several skeletal sites

Typical pattern

Axial skeleton

Predilection for central skeleton

Common distribution

Vertebral column

Especially frequent

Central clinical relevance

“Typically” is not equivalent to “always.”

Slide 24 · Vertebral column is a major site

Vertebral column

Metastases tend to involve the axial skeleton.

Vertebral involvement is especially prominent.

The Batson plexus provides an intraspinal venous route.

The vertebral emphasis does not exclude appendicular lesions.

Schematic spine; Vertebral predilection is based on the supplied text.

Slide 25 · Multifocal disease: Interpret the pattern

Multiple skeletal deposits are characteristic of metastatic disease.

Distribution is most often axial, especially vertebral.

Multiplicity supports the pattern described but is not itself proof of a particular primary.

Clinical implication

A solitary finding does not exclude metastatic cancer.

Slide 26 · Solitary metastasis: Recognized exceptions

Usual picture

Multiple osseous foci.

Axial predilection.

Often indicative of disseminated malignant disease.

Important exceptions

Renal carcinoma may present as a solitary bone focus.

Thyroid carcinoma may present as a solitary bone focus.

A single lesion cannot automatically be labeled primary bone cancer.

This exception is explicitly noted by Robbins.

Slide 27 · Distribution and primary tumor are related clues

Clinical pattern

Supported interpretation

Limit of inference

Multifocal axial lesions

Typical of skeletal metastases

Does not identify primary site

Solitary lesion

Possible with kidney or thyroid carcinoma

Does not exclude metastasis

Vertebral lesion

Common site of metastasis

Route cannot be known by site alone

Any skeletal lesion

Any cancer may involve bone

Imaging appearance is not definitive

Reasoning table derived from the textbook, not a formal diagnostic algorithm.

Slide 28 · Radiographic skeletal responses: Three categories

Osteolytic

Bone destruction predominates

Osteoblastic

Bone formation predominates

Mixed

Both responses coexist

Schematic illustration only — not radiographs, microscopy, or patient images.

Slide 29 · Osteolytic response: Bone destruction

Radiographic lytic lesions represent a bone-destroying pattern.

Osteoclast activation is the proximate mechanism.

Metastatic tumor cells are not depicted as directly digesting bone.

Lytic morphology is an expression of tumor–bone interaction.

Causal distinction

Tumor-derived factors → osteoclast activation → resorption

Slide 30 · Osteoblastic response: New bone formation

Blastic lesions show a bone-forming rather than bone-destroying dominant response.

Tumor-secreted Wnt proteins may promote osteoblast-driven bone formation.

An osteoblastic appearance remains a metastatic pattern, not proof of a primary bone tumor.

Key term

Blastic refers to the skeletal response, not the tissue of origin.

Slide 31 · Mixed response: Resorption and formation coexist

A single metastatic lesion may show lytic and blastic features together.

The three radiographic categories reflect the balance of bone responses.

The categories classify morphology, not separate malignant lineages.

Avoid a false binary

Bone formation and resorption are continuously regulated processes.

Slide 32 · Primary-source associations are tendencies

Primary tumor

Pattern

Additional distribution clue

Prostatic adenocarcinoma

Predominantly blastic

None specified in this paragraph

Kidney carcinoma

Lytic

May be solitary

Breast carcinoma

Lytic pattern described

No exception specified

Thyroid carcinoma

Not classified here

May be solitary

Not a rule-out table: Real lesions may differ and the source does not offer diagnostic sensitivity.

Slide 33 · Prostatic adenocarcinoma and blastic lesions

Prostatic carcinoma

Metastatic cancer

Tumor–bone signals

Osteoblast-directed response

Blastic deposits

New bone formation predominates

Prostatic adenocarcinoma as an example of predominantly blastic skeletal metastasis.

Slide 34 · Kidney carcinoma: Lytic and sometimes solitary

Skeletal response

Kidney carcinoma is cited as producing lytic lesions.

Bone destruction reflects osteoclast-mediated resorption.

The radiographic pattern is not unique to renal cancer.

Skeletal distribution

Renal carcinoma may present with solitary skeletal metastasis.

Multiplicity is therefore not obligatory.

Site-of-origin inference needs caution.

Both features are directly supported by the supplied topic section.

Slide 35 · Breast carcinoma in the supplied examples

Breast carcinoma among the common adult sources.

It is also named among carcinomas producing lytic skeletal lesions.

The same section notes that metastatic breast cancer may sometimes be managed for years with hormone therapy.

Wording precision

The paragraph does not claim that all breast metastases are exclusively lytic.

Slide 36 · Imaging pattern is not a stand-alone diagnosis

Useful morphologic description

Lytic: Destruction predominates.

Blastic: Formation predominates.

Mixed: Both processes are evident.

Unsupported leap

“Blastic = always prostate.”

“Lytic = always kidney.”

“Solitary = cannot be metastatic.”

Interpretive cautions, not additional formal criteria.

Slide 37 · Tumor–bone crosstalk drives lesion phenotype

Metastatic tumor

Secretes signals

Native bone cells

Osteoclast / osteoblast response

Matrix remodeling

Lytic or blastic pattern

The microenvironment helps determine the radiographic phenotype.

Slide 38 · Indirect osteolysis: The central mechanism

Metastatic tumor cells

Prostaglandins · cytokines · PTHrP

Osteoclast stimulation

Bone resorption / osteolysis

Original editable conceptual schematic; Relationships are drawn from the supplied Robbins section.

Slide 39 · Three groups of tumor-derived osteolytic signals

Prostaglandins

Secreted by metastatic cells

Promote osteoclast activity

Cytokines

Tumor-associated signaling molecules

Contribute to osteoclast stimulation

PTH-related peptide

PTHrP

Stimulates osteoclast activity

The source lists mediator classes; Relative contributions are not quantified.

Slide 40 · Why direct tumor erosion is misleading

Too-simple model

Tumor cells directly resorb the bone matrix.

Ignores essential skeletal effector cells.

Fails to explain tumor–host reciprocity.

Robbins model

Metastatic cells release soluble factors.

Osteoclasts carry out enhanced resorption.

Resorbed matrix releases factors useful to tumor cells.

Contrasting mechanistic models, not comparative experimental data.

Slide 41 · Osteoclasts are the immediate resorptive effectors

Tumor-secreted factors

Prostaglandins, cytokines, PTHrP

Osteoclast activation

Enhanced cell activity

Bone loss

Lytic lesion phenotype

The distinction between signal producer and effector cell is central to this mechanism.

Slide 42 · Resorbed bone matrix is biologically active

Bone matrix is a reservoir of growth factors.

Osteoclastic resorption liberates factors that were bound within the matrix.

Released signals can support further metastatic tumor growth.

Therefore bone destruction can favor the cancer, not merely damage skeletal structure.

Released factors

TGF-β

IGF-1

FGF

Slide 43 · Matrix-bound factors described in the text

Factor

Textbook context

Functional implication

TGF-β

Released during bone resorption

Supports metastatic tumor growth

IGF-1

Matrix-derived after resorption

Supports metastatic tumor growth

FGF

Matrix-derived after resorption

Supports metastatic tumor growth

The exact relative or pathway-specific effects are not quantified in the excerpt.

Slide 44 · The osteolytic positive-feedback cycle

Metastatic tumor cells

Osteoclast activation

Bone resorption

Matrix growth factors

TGF-β · IGF-1 · FGF

Original editable conceptual schematic; Relationships are drawn from the supplied Robbins section.

Slide 45 · A feedback loop rather than one-way injury

Metastatic cells can increase osteoclast activity through secreted signals.

Osteoclasts resorb bone and liberate matrix-stored growth factors.

Those factors can support metastatic cancer cells.

The result is a biologically plausible reinforcing interaction.

Two directions

Tumor → bone

Bone → tumor

Slide 46 · Osteoblastic metastasis: Wnt-linked response

Tumor-cell Wnt proteins

Osteoblast stimulation

Increased bone formation

Original editable conceptual schematic; Relationships are drawn from the supplied Robbins section.

Slide 47 · How the mechanisms differ

Dimension

Lytic predominance

Blastic predominance

Primary effector

Osteoclast

Osteoblast

Skeletal response

Bone resorption

Bone formation

Illustrative mediator

PTHrP, prostaglandins, cytokines

Tumor-secreted Wnt proteins

Typical example

Kidney carcinoma

Prostatic adenocarcinoma

Mechanistic examples are not comprehensive inventories.

Slide 48 · Mixed metastasis as a balance of processes

Tumor signaling

Multiple interaction pathways

Osteoclast response

Resorption component

Osteoblast response

Formation component

Mixed bone lesion

Both features coexist

Mixed appearance does not imply two different tumors are present.

Slide 49 · Why skeletal spread changes prognosis

Extraosseous malignancy

Primary cancer established

Skeletal metastasis

Secondary involvement of bone

Disease dissemination

Generally adverse prognostic implication

The prognostic statement is general and must be tempered by tumor type and treatment response.

Slide 50 · Prognostic heterogeneity matters

Overall interpretation

Bone metastasis generally implies dissemination.

Prognosis as generally poor.

An adverse prognostic sign is not an individual survival estimate.

Important qualification

Breast and prostate cancer may respond to hormonal treatment.

Some patients may be managed for many years.

Outcome is not uniform across primary tumor types.

No numerical survival estimate appears in the supplied excerpt.

Slide 51 · Management targets several disease compartments

Systemic tumor

Chemotherapy or immunotherapy

Treat disseminated malignant cells

Local skeletal disease

Localized radiation

Target a symptomatic site

Bone consequences

Bisphosphonates

Fracture stabilization surgery

Treatment options are listed; Details of modern regimens are intentionally not supplied.

Slide 52 · Hormone therapy: A textbook qualification

Hormonal treatment may control some metastatic breast and prostate cancers for many years.

This qualification modifies—not abolishes—the generally poor prognostic implication of skeletal spread.

The source does not define drug choice, sequence, biomarkers, or response rates.

Scope

Disease-specific treatment detail is outside this source paragraph.

Slide 53 · Systemic therapy addresses disseminated cancer

Chemotherapy

Listed as a systemic option for cancers with skeletal spread.

Targets malignant disease beyond one osseous focus.

No cancer-specific regimen is detailed.

Immunotherapy

Also listed as a systemic option.

Part of disease-directed treatment selection.

Indications and biomarkers are not specified in this excerpt.

Statements limited to the scope of Robbins’s discussion.

Slide 54 · Localized radiation and bisphosphonates

Localized radiation

Site-directed treatment modality.

Listed for skeletal metastatic disease.

May be combined with systemic management.

Bisphosphonates

Bone-directed treatment option.

Listed in management of metastases.

Does not substitute for treating the cancer.

The excerpt does not give doses, indications, or comparative outcomes.

Slide 55 · Surgery for pathologic fractures

Metastatic bone involvement

Abnormal bone tissue / weakened structure

Pathologic fracture

Mechanical complication

Surgical stabilization

May be necessary

Mechanical structural failure is a separate problem from tumor control.

Slide 56 · Case exercise: Axial multifocal disease

Hypothetical: An adult with a known extraosseous carcinoma has several skeletal lesions, including vertebral lesions.

Which statements are best supported?

This is a characteristic distribution for skeletal metastases.

The pattern alone does not identify the primary carcinoma.

Vertebral involvement is especially common.

Interpret distribution first; Avoid assigning a primary site from anatomy alone.

Slide 57 · Case exercise: Predominantly blastic lesions

Hypothetical: Skeletal metastases in a patient with prostatic adenocarcinoma are predominantly bone forming.

Explain the pathologic phenotype.

The pattern is consistent with the common association.

Bone formation reflects the osteoblastic side of the tumor–bone interaction.

A blastic lesion is not a primary osteoblast tumor by definition.

Tumor-induced osteoblastic activity explains the skeletal appearance.

Slide 58 · Case exercise: A solitary lytic bone focus

Hypothetical: A patient with kidney carcinoma has one lytic skeletal lesion rather than multiple deposits.

Does the solitary pattern refute metastasis?

No. Renal carcinoma is a recognized exception that may give solitary bone metastasis.

A lytic response is also a described association.

Neither feature alone proves tumor origin.

Solitary skeletal involvement remains compatible with renal carcinoma metastasis.

Slide 59 · Case exercise: Metastatic osteolysis

Hypothetical: Metastatic carcinoma cells secrete PTH-related peptide in bone, and an osteolytic lesion develops.

Identify the primary effector of bone destruction.

The tumor contributes a soluble signal.

Osteoclast activation mediates the actual matrix resorption.

Resorption can release matrix growth factors that support tumor cells.

The osteoclast is the immediate resorptive effector.

Slide 60 · Integrated interpretation: Five questions

Origin

Primary extraosseous cancer?

Route

Local, vascular, intraspinal?

Distribution

Axial? Multiple? Solitary?

Response

Lytic, blastic, mixed?

Impact

Prognosis and skeletal complication?

Use each dimension separately; None can substitute for all the others.

Slide 61 · High-yield mechanism synthesis

Observed feature

Mechanistic explanation

Osteolytic metastasis

Tumor signals stimulate osteoclast-mediated resorption

Growth supported by bone loss

Resorption releases TGF-β, IGF-1, and FGF

Osteoblastic metastasis

Tumor-secreted Wnt proteins may stimulate osteoblasts

Mixed lesion

Resorption and new formation coexist

Skeletal fracture

Bone structure is compromised by metastatic involvement

Mechanism table synthesizes the supplied section and remodeling context.

Slide 62 · High-yield clinical synthesis

Question

Textbook-grounded answer

Most common skeletal malignancy?

Metastases from extraosseous cancer

Principal adult primary group?

Prostate, breast, kidney, lung carcinomas (>75%)

Characteristic distribution?

Multifocal, axial, especially vertebral

Solitary metastasis exceptions?

Kidney and thyroid carcinomas

General prognostic significance?

Usually adverse; Tumor-specific treatment response varies

Do not generalize percentages to other populations.

Slide 63 · References and source limits

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. 2026. Chapter 26, “Metastatic Tumors,” p. 1087–1088.

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. 2026. Chapter 26, “Homeostasis and Remodeling,” p. 1065–1066.

This lecture uses the supplied Markdown source. Original chapter PDF and authentic clinical/histopathology assets were not supplied for cross-checking.

Conceptual figures are editable educational schematics, not clinical images.